Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the… Read more
Shield Therapeutics plc (SHIEF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: -0.367x
Based on the latest financial reports, Shield Therapeutics plc (SHIEF) has a cash flow conversion efficiency ratio of -0.367x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.95 Million) by net assets ($27.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shield Therapeutics plc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Shield Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Shield Therapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shield Therapeutics plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ZOO Digital Group plc
PINK:ZDGGF
|
0.019x |
|
Hotel Royal Chihpen
TWO:5704
|
0.032x |
|
InBioGen Co Ltd
KO:101140
|
-0.010x |
|
Cherrybro co.Ltd
KQ:066360
|
0.153x |
|
Fractal Gaming Group AB
ST:FRACTL
|
-0.074x |
|
BuzzFeed Inc
NASDAQ:BZFD
|
0.023x |
|
QUEST RESOUR.HLDG DL-001
F:5ZK
|
N/A |
|
Ruanyun Edai Technology Inc. Ordinary shares
NASDAQ:RYET
|
0.601x |
Annual Cash Flow Conversion Efficiency for Shield Therapeutics plc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Shield Therapeutics plc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-1.32 Million | $-6.77 Million | 5.140x | +308.15% |
| 2023-12-31 | $15.03 Million | $-37.13 Million | -2.470x | +26.55% |
| 2022-12-31 | $5.43 Million | $-18.25 Million | -3.362x | -724.25% |
| 2021-12-31 | $41.03 Million | $-16.74 Million | -0.408x | -782.15% |
| 2020-12-31 | $30.28 Million | $-1.40 Million | -0.046x | +63.44% |
| 2019-12-31 | $32.15 Million | $-4.07 Million | -0.126x | -3486.73% |
| 2018-12-31 | $40.43 Million | $151.00K | 0.004x | +100.95% |
| 2017-12-31 | $41.21 Million | $-16.15 Million | -0.392x | -84.95% |
| 2016-12-31 | $48.40 Million | $-10.26 Million | -0.212x | -194.45% |
| 2015-12-31 | $-18.64 Million | $-4.18 Million | 0.224x | -- |